[The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
IL-2/LAK adoptive immunotherapy is one of new complementary treatments for advanced malignant tumors. This therapy has two main problems: high dose of IL-2 often causes serious side effects and it is difficult to gain enough amount of LAK cells. MPS is a new immunomodulator in cancer immunotherapy. The present study showed that, comparing with IL-2 10(6)U/L only, IL-2 2 x 10(5)U/L plus MPS 0.4mg/L was significantly more effective in activating both the growth of LAK cells and its cytotoxicity against HEP-2 cells. And the ratio of CD25 positive LAK cells cultured in this condition was also higher. This result suggests that MPS plays a role in creasing the membrane receptors of IL-2.
Wang
J
J
Beijing TongRen Hospital.
Zhu
X
X
Chen
J
J
D002455:Cell Division / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007822:Laryngeal Neoplasms / Q000473:pathology*; D009161:Mycobacterium; D011135:Polysaccharides, Bacterial / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011135:Polysaccharides, Bacterial; D011994:Recombinant Proteins